We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTIC
2101
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $92K | ﹤0.01% |
15,365
| – | – |
|
2102
AvePoint
AVPT
$2.78B
| $88K | ﹤0.01% |
20,191
+6,230
| +45% | +$31.6K |
|
2103
Marathon Digital Holdings
MARA
$3.65B
| $88K | ﹤0.01% |
16,390
-719
| -4% | -$9.62K |
|
2104
Atossa Therapeutics
ATOS
$23.7M
| $86K | ﹤0.01% |
5,289
-5,835
| -52% | -$91.9K |
|
|
GOCO
2105
DELISTED
GoHealth
GOCO
| $85K | ﹤0.01% |
9,482
-108,720
| -92% | -$1.26M |
|
2106
ARS Pharmaceuticals
SPRY
$582M
| $84K | ﹤0.01% |
19,845
+8,896
| +81% | +$31K |
|
2107
W&T Offshore
WTI
$575M
| $84K | ﹤0.01% |
19,553
-60,716
| -76% | -$341K |
|
2108
Payoneer
PAYO
$2.41B
| $82K | ﹤0.01% |
21,029
+6,609
| +46% | +$29.5K |
|
|
CTLP
2109
DELISTED
Cantaloupe
CTLP
| $81K | ﹤0.01% |
+14,530
| New | +$77.2K |
|
|
SURF
2110
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $81K | ﹤0.01% |
49,606
-400,304
| -89% | -$831K |
|
2111
DHT Holdings
DHT
$2.99B
| $80K | ﹤0.01% |
+13,010
| New | +$76.4K |
|
2112
Advantage Solutions
ADV
$371M
| $78K | ﹤0.01% |
+820
| New | +$99.1K |
|
2113
Information Services Group
III
$251M
| $77K | ﹤0.01% |
+11,416
| New | +$71.9K |
|
2114
Passage Bio
PASG
$14.5M
| $74K | ﹤0.01% |
1,570
-4,849
| -76% | -$226K |
|
2115
Eos Energy Enterprises
EOSE
$1.49B
| $73K | ﹤0.01% |
+60,011
| New | +$123K |
|
2116
American Superconductor
AMSC
$1.53B
| $72K | ﹤0.01% |
+13,928
| New | +$80.7K |
|
|
VAPO
2117
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $70K | ﹤0.01% |
+3,457
| New | +$127K |
|
2118
Fulcrum Therapeutics
FULC
$287M
| $68K | ﹤0.01% |
+13,966
| New | +$136K |
|
2119
Custom Truck One Source
CTOS
$2.43B
| $64K | ﹤0.01% |
11,469
-659
| -5% | -$4.2K |
|
2120
The Beachbody Company
BODI
$74.4M
| $64K | ﹤0.01% |
1,073
+595
| +124% | +$48.2K |
|
2121
Brookdale Senior Living
BKD
$3.24B
| $63K | ﹤0.01% |
+13,871
| New | +$81.9K |
|
2122
WisdomTree
WT
$3.33B
| $62K | ﹤0.01% |
12,318
+4
| +0% | +$23 |
|
|
SPNE
2123
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $60K | ﹤0.01% |
+10,689
| New | +$93.2K |
|
2124
Humacyte
HUMA
$192M
| $59K | ﹤0.01% |
18,366
-1,913
| -9% | -$10.6K |
|
2125
Aligos Therapeutics
ALGS
$45.5M
| $58K | ﹤0.01% |
+1,922
| New | +$65.3K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.